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Abstract
Background: Adrenal corticomedullary mixed tumours are very rare. Its mechanism is rarely reported. Here we report
the first case of a corticomedullary mixed tumour resembling a “small adrenal gland” with distinct arrangement of the
cortical and medullary layers. We further hypothesize regarding the tumorigenic mechanism of this tumour.
Case presentation: A 58-year man had been diagnosed with diabetes and hypertension for 3 years. His 24-h urine
vanillylmandelic acid (VMA) levels were slightly elevated. An abnormal circadian cortisol rhythm was noted, and his
cortisol levels were not suppressed by dexamethasone. Abdominal computed tomography (CT) revealed a right
adrenal gland lesion (diameter, 30 × 38 mm), while an enhanced CT showed enhancement and hypervascularization.
The tumour was positive for adrenocorticotropic hormone, chromogranin A (CGA), and steroidogenic factor-1 (SF-1)
on the tumour surface. Acetaldehyde dehydrogenase 1(ALDH1), CD44, CD133, Nestin, Nerve growth factor receptor
(NGFR), and Sex determining region y-box 9(SOX9) staining were positive. Although administration of medications for
diabetes and hypertension was stopped until surgery was performed, the blood sugar level and blood pressure were
maintained after surgery.
Conclusions: This is the first report about a possible mechanism by which cancer stem cells induce adrenal
corticomedullary tumours.
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Background
The adrenal gland contains a cortex and medulla, which
originate from different germ layers. Thus, most primary
neoplasms of the adrenal gland arise from either adrenal
cortical cells or chromaffin cells of the adrenal medulla,
and adrenal tumours generated by more than one cell
type are rare. Even if two cell types coexist in the adrenal
gland, most often, two separate tumours form. Adrenal
cortex and medulla lesions coexisting in the same tumour
to form adrenal corticomedullary mixed tumours are
rarer. In the approximately 20 cases of adrenal corticome-
dullary mixed tumours reported to date [1–20], tumour
cells were distributed in these tumours in a random and
unorganized fashion [11]. Since cases were limited in
number and little research on the subject, the tumorigenic
mechanism remains unclear. We describe the first case of
a corticomedullary mixed tumour resembling a “small
adrenal gland” with a distinct arrangement of cortical and
medullary layers, and hypothesize that tumour stem cells
may contribute to its development.
Case presentation
A 58-year-old man with a history of type 2 diabetes and
hypertension was admitted in June 2013 because of
headache, loss of appetite, constipation, and wide fluctu-
ations in both blood glucose levels (3.3–25.2 mmol/L)
and blood pressure (147–180/70–120 mmHg) during the
past three months, despite treatment with insulin, metfor-
min, and amlodipine, furthermore, he had undergone
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subtotal gastrectomy for a stomach ulcer 28 years ago.
The patient had no family history of diabetes, hyperten-
sion, malignancies, or other related diseases. Physical
examination revealed a blood pressure of 119/83 mmHg
with no physical signs of moon facies, buffalo hump, trun-
cal obesity, or purple abdominal striae. The CT image
revealed a circular, solid, soft tissue mass measuring 30 ×
38 mm with a clear boundary in the right side of the ad-
renal gland. On contrast enhancement, the lesion appeared
heterogeneous, with no calcification or necrosis. Enhance-
ment and hypervascularization (Fig. 1a) also were observed
(arrow). The radiodensity was 35 hounsfield units (HU) on
unenhanced CT and 80 HU on contrast-enhanced CT.
Continuous glucose monitoring showed wide fluctuations
in blood glucose levels (Fig. 2a), and 24-h urine VMA
levels were slightly elevated (Table 1). These clinical mani-
festations suggested the possibility of pheochromocytoma
[21, 22]. Further workup revealed an abnormal circadian
Fig. 1 CT and immunohistochemistry of the right adrenal lesion. a Abdominal CT image showing a right adrenal lesion (arrow). b Gross
appearance of the resected right adrenal gland, and immunohistochemical double-staining for SF-1 and CGA: the adrenal capsule (ac), residual
normal adrenal cortex (nac; stained brown for SF-1), tumour capsule (tc), cortical component of the tumour (cct; stained brown for SF-1), and
medullary component of the tumour (mct; stained red for CGA) are visible (×200). c-h Immunohistochemical staining for the cancer stem cell-
specific markers ALDH1 (c), CD44 (d), CD133 (e), Nestin (f), NGFR (g), and SOX9 (h) (×400 and × 1000)
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cortisol rhythm and cortisol levels that were not sup-
pressed by dexamethasone (either 1 mg overnight or 2 mg
every 6 h for 2 days), indicating the possibility of Cushing’s
syndrome (Table 1). Other laboratory findings, such as
plasma aldosterone, were normal (Table 1). The right
adrenal lesion was resected laparoscopically after alpha-
adrenergic receptor blockade. Postoperative immunohisto-
chemical staining for SF-1 and CGA confirmed that the
tumour was a corticomedullary mixed tumour. In order to
analyse the tumorigenic mechanism of corticomedullary
mixed tumour with distinct arrangement of the cortical
and medullary layers, we stained the resected tissue for
various tumour stem cell-specific markers, including
ALDH1, CD44, CD133, Nestin, NGFR, and SOX9, and
found short spindle-positive cells scattered within the
tumour (Fig. 1c-h), suggesting the involvement of tumour
stem cells. During 18 months of postoperative follow-up,
the patient did not require hypoglycaemic or antihyper-
tensive drugs and had stable blood glucose levels
(Fig. 2b) and blood pressure. Additionally, the cortisol
rhythm and 24-h urine VMA level returned to normal
(Table 1). Abdominal CT confirmed complete resection
of the tumour (Fig. 2c), and metaiodobenzylguanidine
(Fig. 2d) and positron emission tomography-CT (Fig. 2e)
scans revealed no extra-adrenal lesion. Family history
screening indicated that this was an isolated case
(Fig. 2f ).
Discussion
A corticomedullary mixed tumour is defined as a single
adrenal tumour mass containing an intimately admixed
population of both adrenal cortical cells and pheochro-
mocytes [1]. Corticomedullary mixed tumours are likely
to occur in female [16], and most of them are benign
with a favourable prognosis. However, some malignant
tumours with a poor prognosis have been reported
[16, 20]. Hence, long-term follow-up is needed.
Corticomedullary mixed tumours produce both cortisol
and catecholamine, and therefore, signs and symptoms
may arise from either tumour component. Hypersecretion
of cortical and medullary lesions causes 40% of diabetes
cases, 80% of hypertension cases, and 53.33% of Cushing’s
syndrome cases [20]. The typical clinical manifestations
are easy to identify, however, the lack of specific clinical
manifestations in many cases leads to them often being
discovered accidentally, and ultimately a pathological diag-
nosis is required [13]. Cases similar to that of our patient
may manifest with subclinical Cushing’s syndrome, includ-
ing cortisol rhythm abnormalities, but no typical Cushing’s
syndrome appearance [11]. Nonspecific symptoms, such
Fig. 2 Clinical follow-up datas. a A preoperative continuous glucose monitoring graph. b A postoperative continuous glucose monitoring graph.
c A postoperative CT image showing absence of the right adrenal tumour (arrow). d A metaiodobenzylguanidine scan image. e A positron
emission tomography-CT image. f A pedigree chart
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as headache and flank pain, can increase the difficulty of
diagnosis.
As the adrenal cortex and medulla originate from
different germinal layers [23], cortical and medullary tu-
mours usually develop independently, and the simultan-
eous development of these tumours is rare. Adrenal
corticomedullary mixed tumours are rarer. The tumori-
genic pathogenesis of such is different from synchronous
separate adrenal collision tumours and corticomedullary
mixed tumours with random, unorganized cells structure.
The question of whether the cortical adenoma and pheo-
chromocytoma components of corticomedullary mixed
tumours grow independently, or whether their growth is
interrelated, is difficult to resolve [20], therefore, the
pathogenesis of corticomedullary mixed tumours remains
obscure [16]. The following mechanisms mainly have been
proposed: Firstly, pheochromocytomas secreted ectopic
corticotropin, which might caused adrenal cortical hyper-
plasia and/or adrenal cortical adenoma. Moreover, hyper-
secreted catecholamines stimulated the anterior pituitary
to secrete corticotropin, which may lead to similar adrenal
cortical lesions [13]. Additionally, key enzymes of catechol-
amine synthesis, such as beta hydroxylase, tyrosine hy-
droxylase, and phenylethanolamine-N-methyltransferase
might be regulated by high concentrations of glucocortic-
oid via the intra-adrenal portal system. This induction
leads to increased expression of epinephrine and norepin-
ephrine, thus maintaining a vicious spiral [15]. Besides, re-
searchers speculated that some unknown mechanisms can
destroy the interaction of normal cortical-chromaffin cell
and result in trophic stimulation of both cells [20]. Finally,
genetic mutations in stem cells can lead to adrenal cortical
tumours. Cortical tumours have excessive secretion of corti-
sol, and then leads to induction of the rate limiting enzyme
in catecholamine synthesis, i.e. phenylethanolamine-N-
methyltransferase, mediated medullary hyperplasia [20].
Concurrent cortical and medullary tumours present as
either adrenal collision tumours, in which cortical and
Table 1 The preoperative and postoperative endocrinological evaluation
Parameter Values Reference Range
Preoperative Postoperative
ACTH (ng/L) 21.2 39.5 4.8–48.8
Cortisol (nmol/L) 290 392 176.6–579.4(8 am)
510 196 66–353(4 pm)
635 146 <100(0 am)
LDDST Cortisol (nmol/L) 232 N/P <50
HDDST Cortisol (nmol/L) 679 N/P <145(50% baseline value)
Aldosterone (pg/ml) 42.6 76.3 60–175
UVMA (mg/24h) 16.4 7.60 <13.6
GA (%) 21.64 14.52 11–16
HbA1c (%) 7.7 5.9 4.0–6.0
CPRT (ng/ml) 0 min 0.7 0.79 0.48–0.78
30 min 0.5 5.1 1.3–5.0
60 min 0.6 8.66 1.25–4.6
120 min 1.1 2.17 0.75–3.23
180 min 1.2 0.96 0.37–1.62
FT3 (pmol/L) 2.6 4.2 3.1–6.8
FT4 (pmol/L) 16.6 12.3 11–22
TSH (mIU/L) 1.05 3.96 0.468–4.68
FSH (mIU/ml) 12.29 10.59 0.95–11.95
TEST (nmol/L) 7.73 10.36 1.68–8.11
PROG (ng/ml) <0.1 0.2 <0.1–0.2
PRL (ng/ml) 8.62 26.14 3.46–19.4
E2 (pg/ml) 23 33 11–44
LH (mIU/ml) 4.51 8.88 1.14–8.75
ACTH adrenocorticotrophin, LDDST low-dose dexamethasone suppression test, HDDST high-dose dexamethasone suppression test, UVMA urinary vanillymandelic
acid, GA glycosylated albumin, HbA1c glycosylated haemoglobin; CPRT C- peptide release test, FT3 free triiodothyronine, FT4 free thyroxine, TSH thyroid-
stimulating hormone, FSH follicle-stimulating hormone, TEST testosterone, PROG progesterone, PRL prolactin, E2 estradiol, LH luteinizing hormone, N/P
not performed
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medullary tumours develop independently but in close
proximity without admixture at the interface [22], or
corticomedullary mixed tumours, in which the adrenal
cortical and medullary tumour cells develop within
the same tumour at random, forming a structurally
unorganized tumour without distinct cortical and
medullary layers [11]. However, the present tumour
differed from those previously described, as the cortical
and medullary tumour cells were arranged in distinct
layers resembling a “small adrenal gland” (Fig. 1b). The
unique features of this tumour indicated that its tumori-
genic mechanism might differ from that of other cortico-
medullary mixed tumours, it was likely derived from a
single origin, which was commonly differentiated from
tumor stem cell.
Conclusions
In summary, here we reported the first case of an adrenal
corticomedullary mixed tumour with distinct layers of
cortical and medullary cells resembling a “small adrenal
gland”, which differed from previously reported cortico-
medullary mixed tumour types. We also hypothesize that
tumour stem cells may contribute to the development of
this tumour. Our findings provide a new insight into the
tumorigenic mechanism of adrenal tumours, and may
help future development in adrenal tumour interventions.
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